Tetanus Market

 Market Overview:

The 7 major tetanus markets reached a value of US$ 1.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1.6 Billion by 2034, exhibiting a growth rate (CAGR) of 3.46% during 2024-2034.

The tetanus market has been comprehensively analyzed in IMARC's new report titled "Tetanus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tetanus, also known as lockjaw, refers to a serious bacterial infection caused by the bacterium Clostridium tetani. The bacteria can enter the body through a wound or a cut, and they release a potent toxin that affects the muscles and nerves. The muscles most commonly afflicted are those in the jaw, which can cause difficulty opening the mouth and swallowing. However, the infection can spread to various other parts of the body, causing muscle stiffness and spasms throughout. Some individuals suffering from the disease may also experience a fever, often accompanied by sweating. The diagnosis of tetanus typically relies on a combination of the patient's clinical symptoms, medical history, and laboratory tests. If there is an open wound, a sample might be taken to culture it and identify the presence of bacteria. The healthcare provider may also perform a complete blood count to evaluate any signs of infection or abnormalities in the blood cells. In some cases, electromyography may be further conducted to determine the electrical activity in muscles. This test can help to confirm the presence of muscle spasms and identify the characteristic pattern associated with the condition.

The increasing cases of deep puncture wounds, burns, crush injuries, etc., which provide a suitable breeding ground for the bacteria to multiply, are primarily driving the tetanus market. In addition to this, the rising prevalence of inadequate immunization against the illness that enhances the risk of contracting the infection is also creating a positive outlook for the market. Moreover, the widespread adoption of intravenous antibiotics, such as penicillin, metronidazole, doxycycline, etc., to kill bacteria and prevent the release of hazardous chemicals in patients is further bolstering the market growth. Apart from this, the emerging popularity of neuromuscular blockers, since they work by blocking the transmission of nerve impulses at the myoneural junction to alleviate the severe muscle spasms and rigidity associated with the condition, is acting as another significant growth-inducing factor. Additionally, the inflating demand for tetanus immune globulin (TIG) therapy to neutralize the bacterial toxin and prevent its harmful effects by providing immediate passive immunity against the pathogen is expected to drive the tetanus market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the tetanus market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for tetanus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tetanus market in any manner.

Key Highlights:

• Several nations, including India, Pakistan, Chad, and Somalia, have tetanus infection rates more than 20 per 100,000 people.
• Tetanus affects people of all ages; however, the highest prevalence is seen in babies and young people.
• Tetanus infections occur in high-resource countries, such as the United States, among the unvaccinated or the elderly, who have lost immunity over time.
• Intravenous drug users are also at danger due to contaminated needles or medications.
• Tetanus is more common in agricultural areas and warm temperatures, particularly among males.

Drugs:

ADACEL is recommended for active booster immunization against tetanus, diphtheria, and pertussis (whooping cough) in those aged 4 and above. ADACEL can replace the fifth dose of tetanus, diphtheria, and acellular pertussis vaccine (DTaP) in children aged 4 to 6 years. It can also be combined with Inactivated Poliomyelitis Vaccine (IPV) at separate sites to complete the vaccination series for this age group, if necessary.

BOOSTRIX is a vaccine designed for active booster vaccination against tetanus, diphtheria, and pertussis in people aged 10 and above. It works by increasing the body's immunological response, which produces antibodies and antitoxins against toxoids. Thus, it contributes to immunization or resistance to diphtheria, tetanus, and pertussis illnesses.

DAPTACEL vaccine is recommended for active vaccination against diphtheria, tetanus, and pertussis in a five-dose series for infants and children aged 6 weeks to 6 years. The five-dose immunization series includes a 0.5 mL intramuscular injection given at 2, 4, 6, 15-20 months and 4-6 years of age.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the tetanus market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the tetanus market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current tetanus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the tetanus market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the tetanus market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the tetanus market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of tetanus across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of tetanus by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of tetanus by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with tetanus across the seven major markets?
• What is the size of the tetanus patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of tetanus?
• What will be the growth rate of patients across the seven major markets?
   

Tetanus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for tetanus drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tetanus market?
• What are the key regulatory events related to the tetanus market?
• What is the structure of clinical trial landscape by status related to the tetanus market?
• What is the structure of clinical trial landscape by phase related to the tetanus market?
• What is the structure of clinical trial landscape by route of administration related to the tetanus market?